Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rBCG-N-RSV Vaccine in Adults Over 60 Years of Age
NCT07762014Phase 2Recruiting
- Sponsor
- BioTherVax
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of rBCG-N-RSV vaccine in respiratory syncytial virus infection (RSV), Tuberculosis (TB), sponsored by BioTherVax. Started Sep 2026; status: recruiting.
02
Drugs
rBCG-N-RSV vaccine
03
Conditions
respiratory syncytial virus infection (RSV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07762014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762014.